EGFR and prostate cancer: In several cancer types, e.g., in prostate cancer, lung cancer, gastric cancer, melanoma, and ovarian cancer, the activation by resistin of diverse signaling pathways has been shown, such as those associated with PI-3 K, NFκβ, epidermal growth factor receptor (EGFR), TLR4 receptor, IL-6-dependent STAT3 signaling, pAKT, and Caveolin 1 (Cav-1); it was also revealed also that the presence of miR let-7a, miR-200c, and miR-186 was associated with proliferation [90].